- CGBIO, NDR Medical Technology, forge a partnership in a move
to introduce puncture robot technology and collaborate in
clinical studies.
- CGBIO expects this partnership to gain its stronger
competitiveness in the global digital healthcare market beyond the
presence as a pioneer of AI based healthcare technology.
SEOUL, South Korea,
Sept. 23, 2021 /PRNewswire/
-- CGBIO Inc., a Korea's Regenerative Medicine company,
announced on September 8, 2021 a
successful partnership agreement with NDR Medical Technology, a
Singapore-based company, to
introduce an Automated Needle Targeting (ANT)-X system that
combines Artificial Intelligence (AI) and medical image processing
to assist surgeons during minimally invasive surgery and to
collaborate in clinical studies. With the attendance of a
government official from Enterprise Singapore in a signing
ceremony, CGBIO expects this partnership to be of great help to
promoting the mutual medical technology collaboration between
Singapore and Korea as well as
expanding its globalization strategy of local medical technology in
the years to come.
Under the partnership with NDR, CGBIO will carry out clinical
studies with local prominent doctors as part of efforts to expand
the ANT system in a wide range of interventional procedures that
need percutaneous need placement in urology, orthopedics,
neurosurgery, etc., coupled with a study to finalize the launching
ANT-C, a CT-guided robot.
Graduates from Nanyang Technology founded NDR Medical Technology
in 2015 and developed the world's first AI-empowered interventional
robot systems.
To date, many clinicians themselves have performed their
interventional procedures based on a separate program to assess a
patient's anatomy and conduct trajectory path alignment in
navigating the needle from insertion point to the selected target,
with the problems of insufficient precision and time-consuming
operation time.
The core technology of ANT system is based on NDR's first
interventional robot that integrates C-arm fluoroscopy and CT
imaging to help clinicians achieve safe and accurate percutaneous
needle placement. ANT-X fully automates its system calibration and
the needle alignment with a single X-ray image and allows the
clinicians to focus solely on controlling the depth of insertion.
Less fluoroscopic time due to accurate and quick needle alignment
can result in less radiation exposure for patients and clinicians.
For global expansion, NDR has obtained CE certification for ANT-X
and completed clinical studies in Japan and Southeast Asian countries.
"Many global medical device companies have endeavored to be
partnering with top candidates for AI software-based digital
transformation," said Hyunseung Yu, CEO of CGBIO, adding that
"based on the accumulated Regenerative Medicine technology and
numerous clinical experience hitherto, CGBIO and NDR together will
explore the field of AI-based digital healthcare technology in
Asia. Through our commitment to
providing reliable and accurate medical services to patients, we
count on stronger business competitiveness in the global digital
healthcare market."
Photo - https://mma.prnewswire.com/media/1633164/CGBIO.jpg